1

Gervaise LOIRAND  PhD, Research Director, Inserm

G. Loirand is a vascular biologist who has developed an internationally recognized expertise on vascular smooth muscle cells.
After a PhD (1988, University of Bordeaux, FR) and a postdoctoral stay at the Institute of Molecular Pharmacology (1995–1998; University of Nice Sophia-Antipolis, FR), she joined the laboratory in 1999.
She made a major contribution to the discovery of the role of Rho protein signaling in the pathogenesis of vascular diseases.
She has authored more than 100 articles in peer-reviewed journals. Her research projects are mainly funded by the Agence Nationale de la Recherche (ANR), Fondation pour la Recherche Médicale (Foundation for Medical Research), Fondation de France, and Horizon 2020 research grants.
She was awarded the Jean-Paul Binet Prize from the Foundation for Medical Research in 2012. She chaired the Inserm Scientific committee “Physiology and Physiopathology of Cardiac, Vascular, Pulmonary, Renal and Muscular Systems” from 2012 to 2016.

gervaise.loirand@univ-nantes.fr



1

Vincent SAUZEAU PhD, Researcher, Inserm

V. Sauzeau is an expert in the analysis of intracellular signaling in vascular and airways smooth muscle cells, recognized for its expertise in the role of Rho proteins in physiology and physiopathology.
After obtaining his PhD from the University of Nantes in 2003, he trained as a postdoctoral fellow at the Cancer Research Center in Spain (2004-2009). During this training, he received the Young Investigator and the Spanish biomedical research awards. Recruited by Inserm in 2009, he joined the laboratory of l'institut du thorax. His research is focused on Rho protein signaling and the identification of new therapeutic targets in vascular and pulmonary diseases. His research is funded by national grants and by the technology transfer office Ouest Valorisation.
He has authored or co-authored more than 40 articles in peer-reviewed journals and 6 patents. His achievement has been recognized by pharmaceutical companies: AstraZeneca (Target Innovation Program-2015) and Sanofi (Sanofi Innovation Award Europe-2020).

Vincent.Sauzeau@univ-nantes.fr